Business Wire

SFL

6.2.2020 19:24:11 CET | Business Wire | Press release

Share
SFL posts record results for 2019

Regulatory News:

SFL (Paris:FLY):

 Rental income: €198.7 million (up 3.1% like-for-like)

EPRA earnings: €119.2 million (up 11.8%)

Attributable net profit: €589.8 million

Portfolio value (excl. transfer costs): €7,158 million (up 9.0%)

EPRA NNNAV: €95.9 per share (up 11.1%)

The financial statements for the year ended 31 December 2019 were approved by the Board of Directors of Société Foncière Lyonnaise on 6 February 2020 at a meeting chaired by Juan José Brugera.

2019 business indicators were particularly robust, with rental income and EPRA earnings at a record high as a direct result of strong lettings performances, an excellent occupancy rate and a further reduction in borrowing costs. Added to this, the period saw further gains in the portfolio's appraisal value and the Company's net asset value.

The auditors have completed their audit of the annual financial information and are in the process of issuing their report.

Consolidated data (€ millions)

 

 

 

 

2019

2018

Change

Rental income

198.7

193.5

+2.7%

Adjusted operating profit*

172.8

162.1

+6.6%

EPRA earnings

119.2

106.7

+11.8%

Attributable net profit

589.8

351.6

-

* Operating profit before disposal gains and losses and fair value adjustments

 

 

 

 

 

31/12/2019

31/12/2018

Change

Attributable equity

4,485

4,010

+11.9%

Consolidated portfolio value excluding transfer costs

7,158

6,570

+9.0%

Consolidated portfolio value including transfer costs

7,632

7,005

+8.9%

EPRA NNNAV

4,461

4,017

+11.1%

EPRA NNNAV per share

€95.9

€86.3

Results: business indicators at a record high

Rental income:

Rental income amounted to €198.7 million in 2019 versus €193.5 million the previous year, an increase of €5.2 million (2.7%).

- On a like-for-like basis (excluding all changes in the portfolio affecting year-on-year comparisons), rental income was €5.6 million (3.1%) higher. The increase was attributable to new leases signed in 2018 and 2019, mainly in the Cézanne Saint-Honoré, Washington Plaza and Louvre Saint-Honoré properties, and to index increases.

- Rental income from spaces being redeveloped was down by €2.9 million, mainly reflecting the departure of all the tenants from the 83 Marceau building, which is currently being renovated and remarketed, and the refurbishment of several floors in the 176 Charles de Gaulle building in Neuilly that were vacated at the end of 2018.

- Lastly, income from various penalties was up by €2.4 million, mainly due to the early termination of a lease at 103 Grenelle in the third quarter.

Operating profit before disposals and fair value adjustments to investment property amounted to €172.8 million in 2019, an increase of 6.6% from €162.1 million the year before.

Portfolio appraisal value:

The portfolio’s appraisal value grew by 9.0% over the year, despite the absence of any property acquisitions. The increase led to the recognition of positive fair value adjustments to investment property of €526.9 million in 2019 compared with positive adjustments of €289.0 million in 2018.

Net profit:

Net finance costs amounted to €28.1 million in 2019 versus €52.0 million the previous year. The €23.9 million decrease was primarily due to the high basis of comparison created in 2018 by the non‑recurring costs recorded on €300 million worth of bond buybacks. Recurring finance costs, which came to €26.4 million, declined by a significant €4.2 million over the year, reflecting a further improvement in average refinancing costs.

After taking into account these key items, the Group reported attributable net profit for the year of €589.8 million, versus €351.6 million in 2018.

Excluding the impact of disposals, changes in the fair value of investment property and financial instruments and the related tax effect, the Group’s EPRA earnings rose by a strong 11.8% in 2019 to a record high of €119.2 million compared with €106.7 million the previous year.

Operations: SFL continues to enjoy brisk letting activity in a buoyant market, while development projects move ahead at full pace

Rental operations:

In 2019, the office rental market in the Paris region continued to perform very well, supported by strong demand especially for prime properties, a historically low vacancy rate and rising rental values.

In this environment, SFL signed leases on around 56,000 sq.m. in 2019 on very good terms. The main new leases concerned:

- Louvre Saint-Honoré, with the fulfilment of the conditions precedent of the turnkey lease signed with the Cartier Foundation for 20,100 sq.m. GLA of retail space on the lower floors of the building to be delivered in 2023.

- 106 Haussmann, with approximately 12,000 sq.m. pre-let to WeWork.

- 103 Grenelle, with a total of some 5,000 sq.m. let to several different tenants including ADP, Huawei and Wemanity.

- Edouard VII, with around 2,500 sq.m. let to Netflix.

- 176 Charles de Gaulle in Neuilly, with three refurbished floors let to FHB and Manpower.

In addition, new leases were signed with existing tenants such as GIE Carte Bancaire, Facebook, Zurich Insurance and Edouard Denis Développement, on expiry of their previous lease or to meet their changing needs.

Nominal rents for office leases signed in 2019 averaged €754 per sq.m., with effective rents averaging €659 per sq.m. for an average non-cancellable term of 8.1 years, reflecting the previously mentioned good performance of the rental market and the quality of SFL’s buildings.

The physical occupancy rate for revenue-generating properties continued to hold firm, at 97.4% at 31 December 2019 versus 97.3% a year earlier. The EPRA vacancy rate remained at a very low 1.6%. These ratios confirm SFL’s ability to keep its lettable properties fully occupied.

Development operations:

Properties undergoing development at 31 December 2019 represented roughly 18% of the total portfolio. They consist mainly of the Group’s current three flagship projects concerning:

- Retail space in the Louvre Saint-Honoré complex, for which the planning appeal process for the new building permit obtained in March 2019 has now ended, allowing renovation work to begin in first-half 2020. Delivery is scheduled for 2023 under the turnkey lease signed with the Cartier Foundation.

- The Biome office complex on avenue Emile Zola (approximately 24,500 sq.m.), which will be comprehensively remodelled over the next two years. The planning appeal process for the building permit obtained in May 2018 has ended (the permit is now final). The property has been cleared and prepared for renovation and remodelling work has recently begun, with delivery scheduled for late 2021.

- The office building at 83 avenue Marceau (approximately 9,600 sq.m.), which is in the process of being redeveloped with delivery scheduled for the first half of 2021.

Capitalized work carried out in 2019 totalled €49.9 million and concerned the above three redevelopment projects, as well as the full renovation of several floors in the Washington Plaza, 9 Percier and 176 Charles de Gaulle (Neuilly) buildings.

Portfolio operations:

No properties were purchased or sold during 2019.

Financing: historically low debt and average borrowing costs

Several financing transactions were carried out during the year as part of the process of active debt management. The aim of these transactions was to take advantage of the low interest rate environment to further reduce the Company’s average borrowing costs while also extending the average maturity of its fixed rate hedges.

The €390 million five-year syndicated revolving line of credit set up in June has increased the amount and extended the maturity of the Company’s undrawn confirmed lines of credit, which totalled €990 million at 31 December 2019.

The Company also took advantage of the very low interest rates available in the third quarter of 2019 to increase its fixed rate hedges by setting up forward swaps and a collar on a total notional amount of €300 million expiring between September and November 2026.

In addition, maximum issuance under the negotiable European commercial paper (NEU-CP) programme was increased to €500 million. Issuance under the program amounted to €387 million at 31 December 2019.

Net debt at 31 December 2019 amounted to €1,732 million, compared with €1,688 million at 31 December 2018, representing a loan-to-value ratio of 22.7%. The average maturity of net debt was 4.2 years and the average cost after hedging was 1.4%, down from the year-earlier level. At the same date, the interest coverage ratio stood at 6.6x.

EPRA NNNAV up 11.1%

The consolidated market value of the portfolio at 31 December 2019 was €7,158 million excluding transfer costs, an increase of 9.0% from €6,570 million at 31 December 2018. The increase reflected a targeted narrowing of yields on prime Paris properties, a further increase in rental values resulting from the Company’s good lettings performance during the year, and changes in the status of properties undergoing redevelopment in 2019 with the completion of major administrative and marketing phases.

The average EPRA topped-up net initial yield (NIY) was 3.0% at 31 December 2019, down slightly from 3.2% at 31 December 2018.

EPRA NNNAV stood at €4,461 million or €95.9 per share at 31 December 2019, an increase of 11.1% versus €86.3 per share at 31 December 2018 (after payment of a dividend of €2.65 per share in April 2019).

Dividend

At the Annual General Meeting to be held on 3 April 2020, the Board of Directors will recommend paying a dividend of €2.65 per share.

EPRA indicators

2019

2018

EPRA Earnings (€m)

119.2

106.7

/share

€2.56

€2.29

EPRA Cost Ratio (including vacancy costs)

13.3%

13.9%

EPRA Cost Ratio (excluding vacancy costs)

12.4%

12.6%

31/12/2019

31/12/2018

EPRA NAV (€m)

4,623

4,142

/share

€99.4

€89.0

EPRA NNNAV (€m)

4,461

4,017

/share

€95.9

€86.3

EPRA Net Initial Yield (NIY)

2.7%

2.8%

EPRA topped-up NIY

3.0%

3.2%

EPRA Vacancy Rate

1.6%

1.6%

Alternative Performance Indicators (APIs)

API EPRA earnings

€ millions

2019

2018

Attributable net profit

589.8

351.6

Less:

 

 

Profit (loss) on asset disposals

-

-

Fair value adjustments to investment property

(526.9)

(289.0)

Fair value adjustments to financial instruments, discounting adjustments to debt and related costs

1.7

21.4

Tax on the above items

14.0

5.3

Non-controlling interests in the above items

40.6

17.3

EPRA earnings

119.2

106.7

API EPRA NNNAV

€ millions

31/12/2019

31/12/2018

Attributable equity

4,485

4,010

Treasury shares

8

10

Unrealised capital gains

23

19

Fair value adjustments to fixed rate debt

(55)

(22)

EPRA NNNAV

4,461

4,017

API net debt

€ millions

31/12/2019

31/12/2018

Long-term borrowings and derivative instruments

1,441

1,494

Short-term borrowings and other interest-bearing debt

393

269

Debt in the consolidated statement of financial position

1,834

1,763

Less:

 

 

Current account advances (liabilities)

(50)

(52)

Accrued interest, deferred recognition of debt arranging fees, negative fair value adjustments to financial instruments

1

2

Cash and cash equivalents

(54)

(25)

Net debt

1,732

1,688

More information is available at www.fonciere-lyonnaise.com

About SFL

Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €7.2 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.

Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA

S&P rating: BBB+ stable outlook

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye